Abstract

Simple SummaryEwing sarcoma (ES) is an aggressive childhood tumor for which response to chemotherapy is central to long-term prognosis, but few prognostic markers have been identified. RNA-binding proteins (RBPs) are strong regulators of cell behavior, working, for example, through post-translational modifications of mRNA. In this study, we investigated whether patterns in the RBP levels were related to outcomes in ES patients. A total of three distinct patterns were recognized, and additional modelling suggested that 10 RPBs had predictive value, suggesting that this model could be used in a clinical setting to identify patients with a higher risk of mortality.RNA-binding proteins (RBPs) are important transcriptomic regulators and may be important in tumorigenesis. Here, we sought to investigate the clinical impact of RBPs for patients with Ewing sarcoma (ES). ES transcriptome signatures were characterized from four previously published cohorts and grouped into new training and validation cohorts. A total of three distinct subtypes were identified and compared for differences in patient prognosis and RBP signatures. Next, univariate Cox and Lasso regression models were used to identify hub prognosis-related RBPs and construct a prognostic risk model, and prediction capacity was assessed through time-dependent receiver operating characteristics (ROCs), Kaplan–Meier curves, and nomograms. Across the three RBP subtypes, 29 significant prognostic-associated RBP genes were identified, of which 10 were used to build and validate an RBP-associated prognostic risk model (RPRM) that had a stable predictive value and could be considered valuable for clinical risk-stratification of ES. A comparison with immunohistochemistry validation showed a significant association between overall survival and NSUN7 immunoreactivity, which was an independent favorable prognostic marker. The association of RBP signatures with ES clinical prognosis provides a strong rationale for further investigation into RBPs molecular mechanisms.

Highlights

  • Ewing sarcoma (ES) represents the second-most common primary bone malignancy affecting children and adolescents, with an incidence of 2.9 per million/year [1,2,3]. It is an aggressive tumor typically characterized by a fusion of the Ewing sarcoma breakpoint region 1 (EWSR1) with an erythroblast transformation specific (ETS) transcription factor gene, most frequently (>95%) the friend leukemia virus integration 1 (FLI1) gene [4,5]

  • Data before and after normalization were carefully inspected by principal component analysis (PCA), suggesting the batch effect was successfully removed using ComBat (Figure S1B,C)

  • We found a significant association between NSUN7 immunoreactivity and overall survival (Fisher’s exact test, p = 0.0069, Figure 6A) and that NSUN7 negative cases had a shorter overall survival compared to positive ones

Read more

Summary

Introduction

Ewing sarcoma (ES) represents the second-most common primary bone malignancy affecting children and adolescents, with an incidence of 2.9 per million/year [1,2,3]. It is an aggressive tumor typically characterized by a fusion of the Ewing sarcoma breakpoint region 1 (EWSR1) with an erythroblast transformation specific (ETS) transcription factor gene, most frequently (>95%) the friend leukemia virus integration 1 (FLI1) gene [4,5]. Most types of ES harbors the t (11;22) (q24;q12) chromosomal translocation leading to the EWS–FLI1 fusion transcript.

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call